David Warrow, MD
Ophthalmology · Hagerstown, MDNPI 1275776049
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $54,365 of the $78,340 with a category attached, or 69.4%. Baxter Healthcare accounts for 62.4% of it on its own, with 29 other manufacturers making up the rest. Reporting peaked in 2023 at $32,694 and has fallen 93.5% since, to $2,110 in 2025. Among ophthalmology clinicians in MD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 350 payments — averaging $223.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Baxter Healthcare$49K
- Samsung Bioepis Co., Ltd.$13K
- Bausch & Lomb Americas Inc.$3K
- Alimera Sciences, Inc.$2K
- AbbVie$2K
- Genentech USA, Inc.$1K
- plus $8K from 24 others
Across 259 payments — averaging $38,343 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$5.2M
- Novartis$2.3M
- Eyepoint US, Inc.$1.2M
- Boehringer Ingelheim$281K
- Hoffmann-la Roche Limited$254K
- Roche TCRC, Inc.$223K
- plus $434K from 6 others
What the payments were for
- Consulting fees$54,36569%
- Speaking & faculty fees$1,3902%
- Travel & lodging$10,33713%
- Food & beverage$12,24816%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Baxter Healthcare | 24 | $48,905 |
| Samsung Bioepis Co., Ltd. | 5 | $13,421 |
| Bausch & Lomb Americas Inc. | 29 | $3,240 |
| Alimera Sciences, Inc. | 14 | $1,862 |
| AbbVie(2 entities) | 67 | $1,530 |
| Genentech USA, Inc. | 34 | $1,431 |
| Mallinckrodt Hospital Products Inc. | 19 | $1,302 |
| Apellis Pharmaceuticals, Inc. | 32 | $1,255 |
| Biogen | 33 | $1,176 |
| Harrow Eye, LLC | 28 | $877 |
| Eyepoint US, Inc. | 10 | $431 |
| Regeneron Healthcare Solutions, Inc. | 13 | $371 |
| Sun Pharmaceutical Industries Inc. | 5 | $280 |
| Coherus Oncology, Inc. | 2 | $264 |
| Alcon | 2 | $222 |
| Novartis | 7 | $210 |
| Astellas Pharma US Inc | 3 | $201 |
| Neurotech Pharmaceuticals, Inc. | 2 | $164 |
| Cardinal Health 110 LLC | 1 | $150 |
| Regeneron | 1 | $146 |
| Kala Pharmaceuticals, Inc. | 2 | $144 |
| Oyster Point Pharma, Inc. | 2 | $143 |
| ANI Pharmaceuticals, Inc. | 6 | $137 |
| Astellas Pharma Global Development | 1 | $127 |
| Mallinckrodt Enterprises LLC | 1 | $113 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $106 |
| Sandoz | 3 | $64 |
| Thrombogenics, Inc. | 1 | $34 |
| Spark Therapeutics, Inc. | 1 | $19 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$78,340 in reported general payments places this provider in the 90th percentile of 493 ophthalmology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 323 | $9,766 |
| CombiganBrimonidine Tartrate/Timolol | 14 | $4,540 |
| Ofloxacin | 361 | $4,366 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 19 | $3,752 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 158 | $2,679 |
| Brimonidine Tartrate | 101 | $2,312 |
| Acetazolamide ErAcetazolamide | 27 | $1,628 |
| Ketorolac Tromethamine | 84 | $1,584 |
| Brinzolamide | 12 | $1,402 |
| Atropine Sulfate | 34 | $1,244 |
| Latanoprost | 84 | $666 |
| Timolol Maleate | 32 | $293 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCombigan | $1,530 | $4,54014 claims |
| AlconSimbrinza | $222 | $3,75219 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 493 ophthalmology providers in Maryland.
Other ophthalmology in Hagerstown
- Allen HuHagerstown$379K
- Jay BerdiaHagerstown$38K
- John WroblewskiHagerstown$14K
- Alfred SommerBaltimore$2.9M
- Richard AdlerBaltimore$2.7M
- Peter McDonnellBaltimore$1.4M
- Esen AkpekBaltimore$782K
- Lisa FeulnerBel Air$434K
- Susan BresslerLutherville$341K
- Renee BovelleGlenn Dale$292K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.